Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Aug 19;1(3):otz026. doi: 10.1093/crocol/otz026

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

FIGURE 4. — Repeat plasma OSM was available in 30/35 patients that were assessed for the primary outcome with a repeat nCD64 available in 29/35 patients. (A) The absolute change (delta) in plasma OSM between pre-infliximab (infusion1) and pre-maintenance (infusion4) in patients with early biochemical remission and (B) biochemical nonremission. The one patient with an increase in plasma OSM from baseline to W12 had surgery for an ileal stricture 4 months after starting infliximab. (C) The absolute change in nCD64 between pretreatment and pre-maintenance in patients with early biochemical remission and (D) biochemical nonremission.